Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Competitor Analysis
CHAPTER TWO: INTRODUCTION
Structure and Function of the Skin
Epidermis
Dermis
Subcutaneous Tissue
Epidermal Appendages
Functions of the Skin
Effects of Aging on the Skin
Dermatological Conditions and Treatment
Pharmacokinetics
Drug Absorption
Distribution
Bioavailability
Drug Delivery Methods
Demographics of Skin Disorders, Incidence, and Prevalence
CHAPTER THREE: ISSUES AND TRENDS
Patient Compliance
Cosmetic Dermatologists
Sunscreen Use
Melanoma Survival Rates Falter
Indoor Tanning Issue
Phosphatidylglycerol and Psoriasis
New Filler Options
Consumer Confusion
Genetic Link to Psoriasis
Biologic Dermatology
Rx-to-OTC Switches
Cosmeceuticals
Antioxidants
Polypeptides
Teledermatology
Reimbursement Issues
Market Shift Towards less invasive Procedures
Medi-Spas
Combination therapies Thrive
Competitive, Economic, Social Forces Driving Market Demand
Society’s Obsession with Physical Appearance
Regulatory Influences: US & International
International Authorities
U.S. FDA & Other Regulatory Agencies
Effects of Health Insurance Programs & Treatment Costs
Competitive Influences—Impact on Market & Treatment Modalities
Facial Skin–Bio-Physiology
The “Gray Areas” of Medicine
Laser Therapy
Narrowband Ultraviolet B
Photodynamic Therapy
PYCR1 Gene
Changes in Credit Card Terms
Patient Protection and Affordable Care Act
Thermage
BRAF Gene
New Oral Medications and Research for Acne
Synthetic Lipids for Skin Healing
Importance of Drug Delivery
Industry Consolidation
CHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS .69
Description of Disorders
Description of Products
Benzoyl Peroxide
Description of Products
Current Suppliers
Retinoids
Topical Formulations
All-trans Retinoic Acid (Tretinoin)
Adapalene
Tazarotene
Systemic Formulations
Isotretinoin
Current Suppliers
Antibiotics
Description of Products
Azelaic Acid
Clindamycin
Erythromycin
Metronidazole
Sodium Sulfacetamide
Others
Current Suppliers
Oral Contraceptives
Research and Development
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
Europe
Japan
Rest of World
The Future of the Market
Competitive Analysis
CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS
Overview
Description of Products
Keratolytics
Moisturizers
Retinoids
Sunscreens
Botox and Fillers
Research and Development
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
Europe
Japan
Rest of World
The Future of the Market
Competitive Analysis
CHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS
Overview
Description of Products
Topical Corticosteroids
Systemic Corticosteroids
Other Products
Research and Development
Market Size and Growth
Worldwide Market by Type
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Future of the Market
Competitive Analysis
CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS
Overview
Description of Products
Systemic Formulations
Terbinafine
Itraconazole
Fluconazole
Griseofulvin
Ketoconazole
Echinocandin
Current Suppliers
Topical Formulations
Polyenes
Azoles
Miconazole
Clotrimazole
Ketoconazole
Oxiconazole
Econazole
Sulconazole
Allylamines and Benzylamines
Naftifine
Terbinafine
Butenafine
Other Topical Formulations
Novel Products
Current Suppliers
Research and Development
Market Size and Growth
Worldwide Market by Type
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Future of the Market
Competitive Analysis
CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS
Overview
Description of Products
Antiandrogens
Androgen Inhibitors
Other Treatments
Research and Development
Market Size and Growth
Worldwide Market by Type
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Future of the Market
Competitive Analysis
CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA AND DEPIGMENTING DRUGS
Overview
Description of Products
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Research and Development
The Future of the Market
Competitive Analysis
CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS
Overview
Description of Products
Selected Topical Psoriasis Products
Anthralin
Coal Tar
Methoxsalen
Second-generation Retinoids
Tazarotene
Topical Vitamin D
Vitamin D Analogs
Vanos
Vectical Ointment
Selected Systemic Psoriasis Preparations
Betamethasone
Cortisone Acetate
Cyclosporine
Hydrocortisone
Methotrexate
Olopatadine Hydrochloride
Tacrolimus
Light Therapy
Biologics
Novel Products
Research and Development
Market Size and Growth
Worldwide Market by Type
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Future of the Market
Competitive Analysis
CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS
Overview
Nonmelanoma Skin Cancers
Actinic Keratoses
Basal Cell Carcinoma
Squamous Cell Carcinoma
Cutaneous T-cell Lymphoma
Dysplastic Nevus Syndrome
Malignant Melanoma
Description of Products
5-Fluorouracil
Mechlorethamine/Nitrogen Mustard
Carmustine/BCNU (Topical)
Vinblastine (Intralesional) and Others
Research and Development
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
Europe
Japan
Rest of World
The Future of the Market
Competitive Analysis
CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS
Overview
Antivirals
Antiparasitics
Description of Products
Antivirals
Antiviral Drugs
Immunoenhancing Drugs
Current Suppliers
Antiparasitic Agents
Current Suppliers
Other Skin Related Products
Research and Development
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
Europe
Japan
Rest of World
The Future of the Market
Competitive Analysis
CHAPTER THIRTEEN: WORLD MARKET SUMMARY
Overview
Total Market Size and Forecast
Market Analysis by Country
United States
Europe
Japan
Rest of World
Market and Competitive Analysis
CHAPTER FOURTEEN: CORPORATE PROFILES
AbbVie, Inc.
Allergan
Amgen, Inc.
Anacor Pharmaceuticals, Inc.
Astellas Pharma, Inc.
Bayer AG
Bristol-Myers Squibb
Galderma S.A.
Genentech, Inc.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Company, Inc.
Mylan N.V
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
PharmaDerm
Stiefel
Sinclair IS Pharma Plc.
Stratus Pharmaceuticals, Inc.
Valeant Pharmaceuticals International
APPENDIX
LIST OF COMPANIES
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1
The Worldwide Market for Prescription Dermatological Drugs 2013, 2015, and
2020
Figure 1-1
The Worldwide Market for Prescription Dermatological Drugs 2013, 2015, and
2020
CHAPTER TWO: INTRODUCTION
Table 2-1
Common Bases for Topical Dermatological Medications
Table 2-2
Worldwide Incidence and Prevalence of Selected Dermatologic Conditions
CHAPTER THREE: ISSUES AND TRENDS
Table 3-1
Selected Dermatological Rx-to-OTC Switches
Table 3-2
Cy 2015 Relative Value Units (Rvus) and Related Information Used In Determining Final Medicare Payments
CHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS
Table 4-1
Common Benzoyl Peroxide Formulations
Table 4-2
Common Retinoid Formulations
Table 4-3
Common Topical Antibiotic Formulations
Table 4-3 (continued)
Common Topical Antibiotic Formulations
Table 4-3 (continued)
Common Topical Antibiotic Formulations
Table 4-4
Common Oral Contraceptive Formulations
Table 4-5
Prescription Acne, Actinic Keratosis and Rosacea Formulations in Development
Table 4-6
The Worldwide Market for Prescription Acne and Rosacea Drugs by Type 2013- 2020
Figure 4-1
The Worldwide Market for Prescription Acne and Rosacea Drugs Revenues by Type, 2013-2020
Figure 4-2
The Worldwide Market for Prescription Acne and Rosacea Drugs Share by Type 2015
Figure 4-3
The Worldwide Market for Prescription Acne and Rosacea Drugs Share by Type 2020
Table 4-7
Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015 (in millions $)
Table 4-8
Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015 (in millions $)
Table 4-9
The Worldwide Market for Prescription Antiacne and Rosacea Drugs by Geographical Region 2013-2020
Figure 4-4
The Worldwide Market for Prescription Antiacne and Rosacea Drugs Revenues by Geographical Region 2013-2020
Figure 4-5
The Worldwide Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2015
Figure 4-6
The Worldwide Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2020
Table 4-10
Worldwide Market for Prescription Antiacne and Rosacea Drugs Revenues and Market Share by Supplier 2015
Figure 4-7
Worldwide Market for Acne and Rosacea Drugs Market Share by Leading Supplier 2015
CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS
Table 5-1
Common Prescription Keratolytic Formulations
Table 5-2
Occlusive Moisturizers—Categories of Ingredients
Table 5-3
Common Prescription Moisturizers
Table 5-4
Common Prescription Retinoids for Antiaging and Photodamage
Table 5-5
Common Prescription Sunscreens
Table 5-6
Other Prescription Antiaging and Photodamage Products
Table 5-7
Prescription Antiaging and Photodamage Formulations in Development
Table 5-8
The Worldwide Market Antiaging and Photodamage Drugs by Type 2013-2020
Figure 5-1
The Worldwide Market for Antiaging and Photodamage Drugs Revenues by
Type 2013-2020
Figure 5-2
The Worldwide Market for Antiaging and Photodamage Drugs Share by Type 2015
Figure 5-3
The Worldwide Market for Antiaging and Photodamage Drugs Share by Type 2020
Table 5-9
Top Five EU Countries Prescription Antiaging and Photodamage Drug Markets by Revenues and Percent 2015
Table 5-10
Top Four Rest of World Countries Prescription Antiaging and Photodamage Drug Markets by Revenues and Percent 2015
Table 5-11
The Worldwide Market for Prescription Antiaging and Photodamage Drugs by Geographical Region 2013-2020
Figure 5-4
The Worldwide Market for Prescription Antiaging and Photodamage Drugs, Revenues by Geographical Region 2013-2020
Figure 5-5
The Worldwide Market for Antiaging and Photodamage Drugs Share by Geographical Region 2015
Figure 5-6
The Worldwide Market for Antiaging and Photodamage Drugs Share by Geographical Region 2020
Table 5-12
Worldwide Market for Prescription Antiaging and Photodamage Drugs Revenues and Market Share by Supplier 2015
Figure 5-7
Worldwide Market for Prescription Antiaging and Photodamage Drugs, Market Share by Leading Supplier 2015
CHAPTER SIX:
PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS
Table 6-1
Common Prescription Topical Corticosteroid Preparations
Table 6-1 (continued)
Common Prescription Topical Corticosteroid Preparations
Table 6-2
Common Prescription Systemic Corticosteroids
Table 6-3
Prescription Other Dermatitis Formulations
Table 6-4
Prescription Dermatitis Formulations in Development
Table 6-5
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs by Type 2013-2020
Figure 6-1
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Type 2013-2020
Figure 6-2
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2015
Figure 6-3
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2020
Table 6-6
Top Five EU Countries Prescription Dermatitis and Seborrhea Drug Markets by Revenues and Percent 2015 (in millions $)
Table 6-7
Top Four Rest of World Countries Prescription Dermatitis and Seborrhea Drug Markets by Revenues and Percent 2015 (in millions $)
Table 6-8
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs by
Geographical Region 2013-2020
Figure 6-4
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Geographical Region 2013-2020
Figure 6-5
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2015
Figure 6-6
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2020
Table 6-9
Worldwide Market for Prescription Dermatitis and Seborrhea Drugs, Revenues and Market Share by Supplier 2015
Figure 6-7
Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Market
Share by Leading Supplier 2015
CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS
Table 7-1
Common Prescription Systemic Antifungal Dermatological Formulations
Table 7-2
Common Prescription Topical Antifungal Dermatological Drugs
Table 7-3
Prescription Antifungal Dermatological Drugs in Development
Table 7-4
The Worldwide Market for Prescription Antifungal Dermatological Drugs by Type 2013-2020
Figure 7-1
The Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues by Type 2013-2020
Figure 7-2
The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Type 2015
Figure 7-3
The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Type 2020
Table 7-5
Top Five EU Countries Prescription Dermatological Antifungal Drug Markets by Revenues and Percent 2015
Table 7-6
Top Four Rest of World Countries Prescription Dermatological Antifungal Drug Markets by Revenues and Percent 2015
Table 7-7
The Worldwide Market for Prescription Antifungal Dermatological Drugs by Geographical Region 2013-2020
Figure 7-4
The Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues by Geographical Region 2013-2020
Figure 7-5
The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2015
Figure 7-6
The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2020
Table 7-8
Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues and Market Share by Supplier 2015
Figure 7-7
Worldwide Market for Prescription Antifungal Dermatological Drugs Market Share by Leading Supplier 2015
CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS
Table 8-1
Common Prescription Hair Loss or Hair Removal Formulations
Table 8-2
Prescription Hair Loss or Hair Removal Formulations in Development
Table 8-3
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs by Type 2013-2020
Figure 8-1
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Type 2013-2020
Figure 8-2
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2015
Figure 8-3
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2020
Table 8-4
Top Five EU Countries Prescription Dermatological Hair Loss and Hair Removal Drug Markets by Revenues and Percent 2015
Table 8-5
Top Four Rest of World Countries Prescription Dermatological Hair Loss and Hair Removal Drug Markets by Revenues and Percent 2015
Table 8-6
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Revenues by Geographical Region 2013-2020
Figure 8-4
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Revenues by Geographical Region 2013-2020
Figure 8-5
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Geographical Region 2015
Figure 8-6
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Share by Geographical Region 2020
Table 8-7
Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Revenues and Market Share by Supplier 2015
Figure 8-7
Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Market Share by Leading Supplier 2015
CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA AND DEPIGMENTING DRUGS
Table 9-1
Common Prescription Hyperpigmentation/Melasma Formulations
Table 9-2
Common Prescription Depigmenting Agents
Table 9-3
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs by Type 2013-2020
Figure 9-1
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs Revenues by Type 2013-2020
Figure 9-2
The Worldwide Market for Prescription Hyperpigmentation/ Melasma and Depigmenting Drugs, Share by Type 2015
Figure 9-3
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs Share by Type 2020
Table 9-4
The Worldwide Market for Prescription Hyperpigmentation/Melasma Drugs by Geographical Region 2013-2020
Figure 9-4
The Worldwide Market for Prescription Hyperpigmentation/Melasma Drugs Revenues by Geographical Region 2013-2020
Figure 9-5
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs, Share by Geographical Region 2015
Figure 9-6
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs, Share by Geographical Region 2020
CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS
Table 10-1
Selected Common Prescription Psoriasis Preparations
Selected Common Prescription Psoriasis Preparations
Table 10-2
Common Prescription Biologics for Psoriasis Treatment
Table 10-3
Prescription Psoriasis Preparations in Development
Table 10-3 (cont)
Prescription Psoriasis Preparations in Development
Table 10-4
The Worldwide Market for Prescription Psoriasis Drugs by Type 2013-2020 273
Figure 10-1
The Worldwide Market for Prescription Psoriasis Drugs Revenues by Type 2013-2020
Figure 10-2
The Worldwide Market for Prescription Psoriasis Drugs Share by Type 2015 275
Figure 10-3
The Worldwide Market for Prescription Psoriasis Drugs Share by Type 2020 276
Table 10-5
Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015
Table 10-6
Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015
Table 10-7
The Worldwide Market for Prescription Psoriasis Drugs by Geographical Region 2013-2020
Figure 10-4
The Worldwide Market for Prescription Psoriasis Drugs Revenues by Geographical Region 2013-2020
Figure 10-5
The Worldwide Market for Prescription Psoriasis Drugs Share by Geographical Region 2015
Figure 10-6
The Worldwide Market for Prescription Psoriasis Drugs Share by Geographical Region 2020
Table 10-8
Worldwide Market for Prescription Psoriasis Drugs Revenues and Market Share by Supplier 2015
Figure 10-7
Worldwide Market for Prescription Psoriasis Drugs Market Share by Leading Supplier 2015
CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS
Table 11-1
Malignant Conditions of the Skin
Table 11-2
Common Prescription Topical, Intralesional and Other Skin Cancer Agents . 296
Table 11-3
Prescription Skin Cancer Preparations in Development
Table 11-3 (continued)
Prescription Skin Cancer Preparations in Development
Table 11-4
The Worldwide Market for Skin Cancer Drugs 2013-2020
Figure 11-1
The Worldwide Market for Skin Cancer Drugs 2013-2020
Table 11-5
Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015
Table 11-6
Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015
Table 11-7
The Worldwide Market for Prescription Skin Cancer Drugs by Geographical Region 2013-2020
Figure 11-2
The Worldwide Market for Prescription Skin Cancer Drugs Revenues by Geographical Region 2013-2020
Figure 11-3
The Worldwide Market for Prescription Skin Cancer Drugs Share by Geographical Region 2015
Figure 11-4
The Worldwide Market for Prescription Skin Cancer Drugs Share by Geographical Region 2020
Table 11-8
Worldwide Market for Prescription Skin Cancer Drugs Revenues and Market Share by Supplier 2015
Figure 11-5
Worldwide Market for Skin Cancer Drugs Market Share by Leading Supplier 2015
CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS
Table 12-1
Common Prescription Dermatological Systemic and Topical Antiviral
Formulations
Table 12-2
Common Prescription Topical Antiparasitic Formulations
Table 12-3
Common Prescription Other Skin Formulations
Table 12-4
Prescription Miscellaneous Skin Preparations in Development
Table 12-5
The Worldwide Market for Prescription Miscellaneous Skin Disorder Drugs by Type 2013-2020
Figure 12-1
The Worldwide Market for Miscellaneous Skin Disorder Drugs Revenues by Type 2013-2020
Figure 12-2
The Worldwide Market for Miscellaneous Skin Disorder Drugs Share by Type 2015
Figure 12-3
The Worldwide Market for Miscellaneous Skin Disorder Drugs Share by Type 2020
Table 12-6
Top Five EU Countries Prescription Miscellaneous Skin Disorder Drug Markets by Revenues and Percent 2015
Table 12-7
Top Four Rest of World Countries Prescription Miscellaneous Skin Disorder Drug Markets by Revenues and Percent 2015
Table 12-8
The Worldwide Market for Prescription Miscellaneous Skin Disorder Drugs by
Geographical Region 2013-2020
Figure 12-4
The Worldwide Market for Prescription Miscellaneous Drugs Revenues by Geographical Region 2013-2020
Figure 12-5
The Worldwide Market for Prescription Miscellaneous Drugs Share by Geographical Region 2015
Figure 12-6
The Worldwide Market for Prescription Miscellaneous Drugs Share by Geographical Region 2020
CHAPTER THIRTEEN: WORLD MARKET SUMMARY
Table 13-1
The Worldwide Market for Prescription Dermatological Drugs, Revenues by Segment, 2013-2020
Figure 13-1
The Worldwide Market for Prescription Dermatological Drugs Revenues by Dermatological Segment 2013-2020
Figure 13-2
The Worldwide Market for Dermatological Drugs Market Share by Type 2015
Figure 13-3
The Worldwide Market for Dermatological Drugs Market Share by Type 2020
Table 13-2
Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2015
Figure 13-4
Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2015
Figure 13-5
Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2020
Table 13-3
Worldwide Market for Prescription Dermatological Drugs Segments of Major Participation by Manufacturer 2015
Table 13-4
Worldwide Market for Prescription Dermatological Drug Revenues and Market Share by Supplier 2015
LIST OF COMPANIES
